CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials

NV-387Neutral
AI Analysis

Summary

NanoViricides, Inc. has filed its annual report. The company's broad-spectrum antiviral candidate NV-387 is in Phase 2 clinical trials.

Clinical Trial Data

Phase

Phase 2

Importance:2/10
Sentiment:
0.00
antiviralPhase 2annual reportNV-387
Related Companies

Read the original article

Published by yahoo_finance on September 29, 2026 12:45 PM

Read Original